Skip to content

New strategy and application of enriching plasma small fragment cfdna in liquid biopsy

New strategy and application of enriching plasma small fragment cfdna in liquid biopsy

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039298
Enrollment
Unknown
Registered
2020-10-22
Start date
2020-10-30
Completion date
Unknown
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Gold Standard:MagMAX Cell-Free Total Nucleic Acid Isolation Kit
analysis&#32
of&#32
ALU115&#32
and&#32
ALU247&#32
was&#32
using&#32
a&#32
kit&#32
(TB&#32
Premix&#32
Ex&#32
Taq&#32
(Tli&#32
RNaseH&#32

Sponsors

Yongchuan Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. All CRC patients with different stages of CRC and hyperplastic polyps confirmed by imaging and pathology did not receive preoperative radiotherapy and chemotherapy; 2. All patients had no family history of adenomatous polyps or colorectal cancer; 3. The subjects with good compliance should cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with chronic inflammatory diseases such as proctitis and Crohn's disease; 2. Patients with immune diseases such as systemic lupus erythematosus; 3. Patients with severe infection; 4. Pregnant patients with severe heart, liver and lung diseases or poor compliance.

Design outcomes

Primary

MeasureTime frame
intensity;SEN, SPE, ACC, AUC of ROC;

Secondary

MeasureTime frame
ALU115;ALU247;

Countries

China

Contacts

Public ContactJuan Liao

Yongchuan Hospital Affiliated to Chongqing Medical University

liaojuan26@hospital.cqmu.edu.cn+86 23-85381760

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026